Blood consult: Acute myeloid leukemia and the t(8;21)(q22;22)

Blood

Volumn 117, Issue 10, 2011, Pages 2775-2777

  Park, Jae H ^a   Hedvat, Cyrus V ^a   Tallman, Martin S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METOPROLOL; VALSARTAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD; BLOOD EXAMINATION; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME 22Q; CONSULTATION; CONTINUOUS INFUSION; CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA; CYTOGENETICS; ERYTHROCYTE TRANSFUSION; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOPHENOTYPING; LABORATORY TEST; LEUKEMIA REMISSION; MALE; MOLECULAR GENETICS; NEUTROPENIA; PANCYTOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BRUISING; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 79953124101     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-326819     Document Type: Article

References (10)

1. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
2. Rowe JM, Kim HT, Cassileth PA, et al. Adult patents with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Group. Cancer. 2010;116(2):5012-5021.
3. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo acute myeloid leukemia. Leukemia. 1995;9(9):1491-1498.
4. Daniels JT, Davis BJ, Houde-McGrail L, et al. Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biologic marker? Br J Haematol. 1999;107(2):381-383.
5. Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ, Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol. 1993;11(4):690-697. (Pubitemid 23105677)
6. Nishii K, Usui E, Katayama N, et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia. 2003;17(4):731-737. (Pubitemid 36519369)
7. Boissel N, Leroy H, Brethon B, et al; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBFAML). Leukemia. 2006;20(6):965-970.
8. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-3468.
9. Schlenk RF, Pasquini MC, Pérez WS, et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with the t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transpl. 2008;14(2):187-196.
10. Schittenhelm MM, Shiraga S, Schroeder A et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481. (Pubitemid 43166056)